newsfilter
← Latest News
ACCESS Newswire·

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

CVKD
  • Cadrenal Therapeutics (NASDAQ: CVKD) focuses on rebuilding anticoagulation solutions for high-risk patients with unstable renal function or immune responses, areas largely ignored by major pharmaceutical companies.
  • The company's lead asset, tecarfarin, is a Phase 3-ready oral vitamin K antagonist designed for patients with end-stage kidney disease or left ventricular assist devices, offering stability without the wild swings of warfarin or the renal clearance issues of DOACs.
  • Cadrenal acquired a Factor XIa inhibitor portfolio from eXIthera to expand its capabilities into acute hospital care, utilizing frunexian to manage acute clotting risks while minimizing bleeding penalties.
  • The company acquired VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 development for heparin-induced thrombocytopenia (HIT), which holds Orphan Drug and Fast Track designations.
  • Cadrenal now operates on three distinct scientific pillars: Vitamin K antagonism via tecarfarin, Factor XIa inhibition for acute care, and 12-LOX inhibition for immune-mediated thrombosis.
  • The company's strategy aims to bridge critical gaps in both chronic \& acute anticoagulation management for rare \& high-risk populations without drifting from its central theme of solving difficult clinical problems.
  • The press release includes standard forward-looking statements regarding future clinical development, regulatory milestones, \& potential product commercialization, alongside a disclosure that the content is sponsored by Hawk Point Media Group.